Literature DB >> 18086943

Mineralocorticoid signaling in transition to heart failure with normal ejection fraction.

Brian P Shapiro1, Theophilus E Owan, Selma Mohammed, Martina Kruger, Wolfgang A Linke, John C Burnett, Margaret M Redfield.   

Abstract

Heart failure with normal ejection fraction occurs in elderly patients with hypertensive heart disease. We hypothesized that, in such patients, mineralocorticoid receptor activation accelerates the types of ventricular and vascular remodeling and dysfunction believed important in the transition to heart failure. We tested this hypothesis by administering deoxycorticosterone acetate (DOCA) without salt loading or nephrectomy to elderly dogs with experimental hypertension. Elderly dogs were made hypertensive by renal wrapping. After 5 weeks, dogs were randomly assigned to DOCA (1 mg/kg per day IM; old hypertensive [OH]+DOCA; n=11) or not (OH; n=11) for 3 weeks. At week 8, conscious echocardiography and hemodynamic assessment under anesthesia were performed. DOCA resulted in further increases in conscious blood pressure (P<0.05) without increases in cardiac output or diastolic volume. In the conscious state, effective arterial elastance (P<0.05) and systemic vascular resistance (P=0.06) were increased, and systemic arterial compliance (P<0.05) was decreased in OH+DOCA animals. After anesthesia, instrumentation, and autonomic blockade, blood pressure was lower, whereas left ventricular (LV) systolic elastance, LV diastolic stiffness, and ex vivo myofiber diastolic stiffness were increased in OH+DOCA animals. LV collagen was increased in OH+DOCA animals (P<0.05 for all), but LV mass, LV brain natriuretic peptide, and titin isoform profiles were not. Neither aortic stiffness nor aortic structure was altered in OH+DOCA animals. These findings suggest that age and hypertensive heart disease enhance sensitivity to exogenous mineralocorticoid administration and that mineralocorticoid receptor activation could contribute to the transition to heart failure in elderly persons by promoting increases in LV diastolic and systolic stiffness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086943     DOI: 10.1161/HYPERTENSIONAHA.107.099010

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Congestive heart failure: where homeostasis begets dyshomeostasis.

Authors:  German Kamalov; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

2.  Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".

Authors:  Selma F Mohammed; Tomohito Ohtani; Josef Korinek; Carolyn S P Lam; Katarina Larsen; Robert D Simari; Maria L Valencik; John C Burnett; Margaret M Redfield
Journal:  Circulation       Date:  2010-07-12       Impact factor: 29.690

3.  Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure.

Authors:  Anthony G Garcia; Richard M Wilson; Joline Heo; Namita R Murthy; Simoni Baid; Noriyuki Ouchi; Flora Sam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-06-22       Impact factor: 4.733

4.  Regulation of circulating progenitor cells in left ventricular dysfunction.

Authors:  Barry A Boilson; Katarina Larsen; Adriana Harbuzariu; Sinny Delacroix; Josef Korinek; Harald Froehlich; Kent R Bailey; Christopher G Scott; Brian P Shapiro; Guido Boerrigter; Horng H Chen; Margaret M Redfield; John C Burnett; Robert D Simari
Journal:  Circ Heart Fail       Date:  2010-06-23       Impact factor: 8.790

5.  Sodium restriction in heart failure: benefit or harm?

Authors:  Matthew C Konerman; Scott L Hummel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

6.  Local angiotensin II aggravates cardiac remodeling in hypertension.

Authors:  Jiang Xu; Oscar A Carretero; Tang-Dong Liao; Hongmei Peng; Edward G Shesely; Junxiao Xu; Thomas S Liu; James J Yang; Timothy L Reudelhuber; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

Review 7.  Zinc and the prooxidant heart failure phenotype.

Authors:  Nephertiti Efeovbokhan; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2014-10       Impact factor: 3.105

8.  Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction.

Authors:  Rosita Zakeri; Gilles Moulay; Qiang Chai; Ozgur Ogut; Saad Hussain; Hiroyuki Takahama; Tong Lu; Xiao-Li Wang; Wolfgang A Linke; Hon-Chi Lee; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2016-10-10       Impact factor: 8.790

Review 9.  Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the rough.

Authors:  Samuel W Joffe; Robert A Phillips
Journal:  Curr Heart Fail Rep       Date:  2013-06

10.  Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.

Authors:  Brian P Shapiro; Theophilus E Owan; Selma F Mohammed; Donna M Meyer; Lisa D Mills; Casper G Schalkwijk; Margaret M Redfield
Journal:  Circulation       Date:  2008-08-18       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.